Literature DB >> 8467858

Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla.

D Bouhassira1, D Chitour, L Villanueva, D Le Bars.   

Abstract

The aim of this study was to investigate whether the rostral ventromedial medulla (RVM) participates in the lifting of diffuse noxious inhibitory controls (DNIC) by systemic morphine. The effects of morphine (1 mg/kg i.v.) on DNIC were compared in sham-operated rats and animals with electrolytic lesions of the RVM performed one or three weeks earlier. The C-fibre-evoked responses of spinal dorsal horn convergent neurones were similar in the sham-operated and lesioned animals. DNIC acting on these responses were also similar in these groups. DNIC were similarly reduced naloxone reversibly following morphine injections in sham-operated animals and animals tested one week after lesioning of the RVM. In contrast, DNIC were not significantly altered by morphine in animals tested three weeks after lesioning. The lesions were similar in both groups of animals. This time-dependent attenuation of the effects of morphine indicates that the RVM is not directly involved in the reduction of DNIC induced by systemic morphine. However, it is suggested that lesions in this region can induce a reorganization of brainstem opioidergic systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467858     DOI: 10.1016/0014-2999(93)90775-d

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Neuromuscular function in painful knee osteoarthritis.

Authors:  Carol A Courtney; Michael A O'Hearn; T George Hornby
Journal:  Curr Pain Headache Rep       Date:  2012-12

2.  Chronic morphine increases Fos-positive neurons after concurrent cornea and tail stimulation.

Authors:  Ashlee Robbins; David Schmitt; Barbara J Winterson; Ian D Meng
Journal:  Headache       Date:  2011-09-19       Impact factor: 5.887

3.  Pain-induced analgesia mediated by mesolimbic reward circuits.

Authors:  R W Gear; K O Aley; J D Levine
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

4.  Blockade of opioid receptors in the medullary reticularis nucleus dorsalis, but not the rostral ventromedial medulla, prevents analgesia produced by diffuse noxious inhibitory control in rats with muscle inflammation.

Authors:  Marcos A de Resende; Luis Felipe S Silva; Karina Sato; Lars Arendt-Nielsen; Kathleen A Sluka
Journal:  J Pain       Date:  2011-02-17       Impact factor: 5.820

5.  Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons.

Authors:  Akiko Okada-Ogawa; Frank Porreca; Ian D Meng
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

6.  Responses of neurons in rostral ventromedial medulla to nociceptive stimulation of craniofacial region and tail in rats.

Authors:  Jing-Shi Tang; Chen Yu Chiang; Jonathan O Dostrovsky; Dongyuan Yao; Barry J Sessle
Journal:  Brain Res       Date:  2021-05-28       Impact factor: 3.610

7.  Effects of Transcranial Direct Current Stimulation Block Remifentanil-Induced Hyperalgesia: A Randomized, Double-Blind Clinical Trial.

Authors:  Gilberto Braulio; Savio C Passos; Fabricio Leite; Andre Schwertner; Luciana C Stefani; Ana C S Palmer; Iraci L S Torres; Felipe Fregni; Wolnei Caumo
Journal:  Front Pharmacol       Date:  2018-02-19       Impact factor: 5.810

8.  A study of cortical and brainstem mechanisms of diffuse noxious inhibitory controls in anaesthetised normal and neuropathic rats.

Authors:  Ryan Patel; Anthony H Dickenson
Journal:  Eur J Neurosci       Date:  2019-10-06       Impact factor: 3.386

Review 9.  Reticular Formation and Pain: The Past and the Future.

Authors:  Isabel Martins; Isaura Tavares
Journal:  Front Neuroanat       Date:  2017-07-05       Impact factor: 3.856

Review 10.  Central Nervous System Targets: Supraspinal Mechanisms of Analgesia.

Authors:  K Bannister; A H Dickenson
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.